April 19, 2024

Inside Asia: In Fixing the Economy, China Aims for Low-Hanging Fruit

BEIJING — For all the strong rhetoric, China’s latest policy actions suggest a shift in focus on the economy to mix relatively pain-free overhauls that burnish Beijing’s credentials for change with measures to prop up sagging growth.

While Prime Minister Li Keqiang of China provides a drip-feed of easy changes, he will avoid more radical moves for fear of tipping the Chinese economy over the edge.

Analysts from top government research institutions say there is no reason to doubt the government’s commitment to shifting China’s economy away from an investment- and credit-driven growth model to one that relies more on consumption and innovation.

But the leaders are aware they are walking a fine line, and the economy’s weaker-than-expected performance this year has underlined the need to tread carefully. Overhauls might well secure future growth, but if the leaders push too hard now, they could cause an economic shock that forces Beijing to resort to old-school pump-priming, prolonging the very economic model they are trying to dismantle.

“The government has to safeguard its bottom line in growth while restructuring the economy,” said He Qiang, an economist at the Central University of Finance and Economics in Beijing and an adviser to Parliament. “It’s very difficult to balance. Economic restructuring cannot be achieved overnight and it should be a gradual reform, not a revolution.”

Since President Xi Jinping and Mr. Li were appointed to lead China, they have pressed to wean the country off a diet of breakneck expansion and easy credit that fueled double-digit growth for three decades and catapulted China to the top table of global economies.

Just last week, Mr. Xi was quoted by Xinhua, the state-run news agency, on the need “to deepen reforms in all aspects,” though he also acknowledged the line between “being courageous and walking steadily.”

In a nod to growth concerns, Beijing has unveiled a series of small steps in recent weeks that analysts say are geared to providing quick help to the economy. Last week, Beijing said it would scrap taxes for six million small businesses, speed up railway investment and offer more help to exporters.

That means radical overhauls, like full interest-rate liberalization, are off the table for now, although they may be tackled in October when the Communist Party holds a meeting that will set its economic agenda for the next decade.

Until then, the authorities will reach for low-hanging fruit: uncontroversial changes that move in the right direction and could have some, even if only modest, effects on growth but that are limited in ambition.

The central bank’s decision earlier this month to remove the floor on bank lending rates is an example. It was welcomed as a largely symbolic prelude to removing caps on deposit rates, a much more difficult task that will take time.

The central bank said a deposit insurance program and other preparations are needed before a move is made on deposits; economists said that in addition to concerns that it would squeeze banks’ profits there is also concern about its near-term economic effect.

“They dare not liberalize deposit rates now, as that could push up borrowing costs,” said Liang Youcai, an economist at State Information Center, a government research group. The working assumption is that lending rates would rise to pay for the higher cost of deposits.

China’s leaders have said a slowdown in economic growth is needed for the overhauls to take place, since they will be looking at areas like investment in infrastructure and factories, which ares still the main driver of expansion.

That is why the growth target for this year was cut to 7.5 percent from 8.0 percent.

But the 7.5 percent annual growth of the second quarter was the ninth slowdown in the past 10 quarters and showed that the economy is cutting close to the government’s growth target.

Economists familiar with policy makers’ thinking say that splashing out on big infrastructure projects in the way China did during the global financial crisis is out of question.

Article source: http://www.nytimes.com/2013/07/30/business/global/in-fixing-the-economy-china-aims-for-low-hanging-fruit.html?partner=rss&emc=rss

China Accuses GlaxoSmithKline of Corruption

The Ministry of Public Security said people working for the drug maker had bribed doctors, hospitals and government officials and funneled illicit payoffs through travel agencies, pharmaceutical industry associations and project funding.

The government did not name any executives or give detailed figures. But it said the case involved “huge amounts of money.”

The investigation appears to be part of a broad government crackdown on fraud and corruption involving foreign companies.

The announcement came about a week after the authorities raided offices and detained people working for GlaxoSmithKline in three different cities, including Shanghai, according to the state-run news media.

The government findings released Thursday were unexpected because executives at GlaxoSmithKline had said just last week that an internal investigation of its China operations found no evidence of bribery or corrupt activities.

A spokesman for the company said last week that the company had initiated its own investigation after a whistle-blower at the company came forward this year with allegations of wrongdoing in the China operation.

On Thursday, a spokesman for GlaxoSmithKline said that the company was willing to cooperate with the investigation and that the Chinese announcement represented the first details of the case the company had been informed about.

The company also released a statement saying: “We take all allegations of bribery and corruption seriously. We continuously monitor our businesses to ensure they meet our strict compliance procedures. We have done this in China and found no evidence of bribery or corruption of doctors or government officials. However, if evidence of such activity is provided we will act swiftly on it.”

Earlier this year, The Wall Street Journal reported that a whistle-blower had shared some information with the newspaper and claimed that executives at the company had bribed doctors and hospitals. It is unclear whether the investigation by the Ministry of Public Security is linked to the whistle-blower.

The allegations against GlaxoSmithKline come at a time when regulators in China are reviewing the prices and production costs of major Chinese and global drug companies in what appears to be an effort to lower drug prices.

Feng Zhanchun, who specializes in public health at Huazhong University of Science and Technology in Wuhan, China, said that the Chinese pharmaceutical market was struggling to adapt to market forces.

“Economic crimes, including commercial bribery and kickbacks, are one of the negative results generated in the transitional period in China,” he said in a telephone interview. “In the midst of a transition from a planned economy to a market economy, laws and regulations are not fully in place, and medical institutions have no perfect operational mechanisms.”

China is one of the world’s fastest-growing markets for pharmaceutical products, but the government has long held tight control over pricing of certain drugs.

Still, in a country where kickbacks are common and the sales channels for many products are swayed by bribery, travel vouchers and payoffs, it is not unusual for major corporations to come under scrutiny from Chinese or Western regulators.

In 2012, the American drug maker Eli Lilly agreed to pay $29 million to settle allegations of making improper payments to government officials and physicians in Brazil, China, Poland and Russia.

In the Eli Lilly case, the United States government said employees from the company’s China subsidiary had “falsified expense reports in order to provide gifts and cash payments to government-employed physicians.”

Among other things, the company’s sales representatives used reimbursements to provide doctors with meals, card games and “visits to bath houses.”

In recent years, the U.S. Department of Justice has scrutinized the world’s biggest drug companies to determine whether they have made improper payments to doctors and hospitals around the world in order to increase sales of their drugs.

In the case of GlaxoSmithKline, Chinese investigators seemed to have moved with lightning speed, detaining workers, raiding offices in various cities and then publicizing their findings Thursday.

The authorities said that in order to “open the sales channel and increase prices” in China, GlaxoSmithKline, also called GSK, had bribed or paid off a wide range of people who could aid the company’s sales operations.

Among other things, the China subsidiary of GlaxoSmithKline “committed crimes” by writing special bills related to the value-added tax and issued fake invoices through travel agencies, officials said. The government said there was “ample evidence to show that some senior executives at GSK and certain travel agencies committed several commercial bribery and tax-related crimes.”

The government also said the company’s senior executives had confessed to many of the crimes, including taking kickbacks from business meetings and accepting commission fees through travel agencies.

GlaxoSmithKline’s problems in China deepened earlier this month when the company fired the head of its research and development center in Shanghai for misrepresenting data in a paper he co-wrote.

Stephanie Yifan Yang contributed research.

Article source: http://www.nytimes.com/2013/07/12/business/global/china-accuses-glaxosmithkline-of-corruption.html?partner=rss&emc=rss

GlaxoSmithKline Accused of Corruption by China

The Ministry of Public Security said people working for the drug maker had bribed doctors, hospitals and government officials and funneled illicit payoffs through travel agencies, pharmaceutical industry associations and project financing.

The government did not name any executives or detailed figures. But it said the case involved “huge amounts of money.”

The investigation appears to be part of a broad government crackdown on fraud and corruption involving foreign companies.

The announcement came about a week after the authorities raided offices and detained people working for GlaxoSmithKline in three different cities, including Shanghai, according to the state-run news media.

The government findings released Thursday were unexpected because executives at GlaxoSmithKline had said just last week that an internal investigation of its China operations found no evidence of bribery or corrupt activities.

A spokesman for the company said last week that the company had initiated its own investigation after a whistle-blower at the company came forward this year with accusations of wrongdoing in the China operation.

On Thursday, a spokesman for GlaxoSmithKline said that the company was willing to cooperate with the investigation and that the Chinese announcement represented the first details of the case the company had been informed about.

The company also released a statement saying: “We take all allegations of bribery and corruption seriously. We continuously monitor our businesses to ensure they meet our strict compliance procedures. We have done this in China and found no evidence of bribery or corruption of doctors or government officials. However, if evidence of such activity is provided we will act swiftly on it.”

Like many other large pharmaceutical companies, Glaxo has been investing significantly in China and other emerging markets, seeking to capitalize on a growing middle class that can increasingly afford to pay for prescription drugs.

Although China still accounts for a small fraction of Glaxo’s business, sales in the country grew 17 percent in 2012, to $1.2 billion.

Sales in emerging markets accounted for about a quarter of the company’s business in 2012.

Earlier this year, The Wall Street Journal reported that a whistle-blower had shared some information with the newspaper and claimed that executives at the company had bribed doctors and hospitals.

It is unclear whether the investigation by the Ministry of Public Security is linked to the whistle-blower.

Regulators in China are reviewing the prices and production costs of major Chinese and global drug companies in what appears to be an effort to lower drug prices.

Feng Zhanchun, who specializes in public health at Huazhong University of Science and Technology in Wuhan, China, said that the Chinese pharmaceutical market was struggling to adapt to market forces.

“Economic crimes, including commercial bribery and kickbacks, are one of the negative results generated in the transitional period in China,” he said in a telephone interview. “In the midst of a transition from a planned economy to a market economy, laws and regulations are not fully in place, and medical institutions have no perfect operational mechanisms.”

China is one of the world’s fastest-growing markets for pharmaceutical products, but the government has long held tight control over pricing of certain drugs.

Still, in a country where kickbacks are common and the sales channels for many products are swayed by bribery, travel vouchers and payoffs, it is not unusual for major corporations to come under scrutiny from Chinese or Western regulators.

Stephanie Yifan Yang contributed research.

Article source: http://www.nytimes.com/2013/07/12/business/global/china-accuses-glaxosmithkline-of-corruption.html?partner=rss&emc=rss

As China’s Economy Cools, Loan Sharks Come Knocking

The owner, Sun Fucai — or Boss Sun, as he’s known — was so insistent that his workers attend that he imposed a $30 fine on any employee who refused the getaway. Nearly everyone went.

Except Boss Sun.

When the employees returned from their holiday, they found that the factory had been stripped of its equipment and that Boss Sun had fled town. “It was entirely empty,” Li Heying, a former Aomi worker, said of the factory. “It was like what happens in war time.”

The boss, as it turned out, was millions of dollars in debt to loan sharks — underground lenders of the sort that many private businesses in China routinely use because the government-run banks typically lend only to big state-run corporations.

He was hardly unique. As China’s economy has begun to slow slightly, more and more entrepreneurs are finding themselves in Mr. Sun’s straits — unable to meet debt payments on which interest rates often run as high as 70 percent in this nation’s thriving unregulated, underground loan system. Such illegal lending amounts to about $630 billion a year, or the equivalent of about 10 percent of China’s gross domestic product, according to estimates by the investment bank UBS.

In recent months, at least 90 business executives from this coastal city, a one-hour flight south of Shanghai, have disappeared because of mounting debts and impending bankruptcies, according to a local government report.

Whether out of fear of mafia-style loan enforcers — kidnappings and broken kneecaps are common tactics — or the family dishonor that is its own harsh penalty in China, some of the Wenzhou missing have gone into hiding. Others have fled overseas.

And in the last few weeks, at least three have attempted suicide by jumping off high-rises in the city, according to the state-run news agency, Xinhua, which reported that two of them died and the other survived with a broken leg.

That tycoons in a city known for its savvy entrepreneurs are running scared has raised concerns that private business, a vibrant part of China’s economy, may be losing steam — while exposing the high-risk, unregulated financial system on which so many of the nation’s small and medium-size businesses have come to depend.

“There have always been people running away because they couldn’t pay their debts,” said Wang Yuecai, general manager at Wenzhou Yinfeng Investment Guarantee, a firm that guarantees state bank loans when small businesses are lucky enough to get them. “But recently, the situation here has gotten much worse.”

Last week, Prime Minister Wen Jiabao and a delegation of high-ranking officials, including the head of the nation’s central bank, visited Wenzhou trying to calm the city. The officials promised to get official banks to lend more to small companies and to crack down on underground lenders that charge high interest rates.

And on Wednesday, China’s state council, or cabinet, announced a series of measures aimed at helping small businesses with tax breaks and new lines of credit.

Beijing no doubt worries that similar problems could surface in other parts of the country.

“This is not just happening in Wenzhou,” said Chang Chun, who teaches at the Shanghai Advanced Institute of Finance. “Some companies borrow from the state banks and then lend into the underground market. Many are doing this type of arbitrage.”

But caging the loan sharks could prove difficult, not only because the activity is so rampant but because the lending is in some ways a result of the government’s own banking policies.

Gu Huini contributed research

Article source: http://www.nytimes.com/2011/10/14/business/global/as-chinas-economy-cools-loan-sharks-come-knocking.html?partner=rss&emc=rss